Bristol/AZ Saxagliptin Safety Review: All Signs Point to Positive Committee Outcome

Upcoming FDA advisory committee review of DPP4 inhibitor poses first test of new diabetes cardiovascular safety guidelines. Bristol and AstraZeneca won’t be the only companies watching carefully.